| Pulmonary arterial hypertension
Adempass vs WINREVAIR
Side-by-side clinical, coverage, and cost comparison for pulmonary arterial hypertension.Deep comparison between: Adempas vs Winrevair with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsWinrevair has a higher rate of injection site reactions vs Adempas based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Winrevair but not Adempas, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Adempas
Winrevair
At A Glance
Oral
Three times daily
Soluble guanylate cyclase (sGC) stimulator
Subcutaneous
Every 3 weeks
Activin signaling inhibitor
Indications
- Chronic thromboembolic pulmonary hypertension
- Pulmonary arterial hypertension
- Pulmonary arterial hypertension
Dosing
Chronic thromboembolic pulmonary hypertension, Pulmonary arterial hypertension Start at 1 mg three times a day (or 0.5 mg if hypotension risk); increase by 0.5 mg no sooner than every 2 weeks as tolerated, to a maximum of 2.5 mg three times a day.
Pulmonary arterial hypertension Starting dose 0.3 mg/kg subcutaneously every 3 weeks; target dose 0.7 mg/kg subcutaneously every 3 weeks after verifying acceptable hemoglobin and platelet count. Check hemoglobin and platelets before each dose for the first 5 doses or longer if values are unstable.
Contraindications
- Pregnancy
- Concomitant use of nitrates or nitric oxide donors in any form
- Concomitant use of PDE-5 inhibitors (sildenafil, tadalafil, or vardenafil) or nonspecific PDE inhibitors (dipyridamole or theophylline)
- Concomitant use of other soluble guanylate cyclase (sGC) stimulators
- Pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP)
—
Adverse Reactions
Most common (>=3%) Headache, dyspepsia and gastritis, dizziness, nausea, diarrhea, hypotension, vomiting, anemia, gastroesophageal reflux disease, constipation
Serious Embryo-fetal toxicity, hypotension, bleeding
Most common (>=10%) Headache, epistaxis, rash, telangiectasia, diarrhea, dizziness, erythema, increased hemoglobin
Serious Erythrocytosis, severe thrombocytopenia (platelet count <50,000/mm3), serious bleeding, intrapulmonary right-to-left shunting
Postmarketing Pericardial effusion
Pharmacology
Riociguat is a soluble guanylate cyclase (sGC) stimulator with a dual mode of action: it sensitizes sGC to endogenous nitric oxide (NO) by stabilizing the NO-sGC binding, and directly stimulates sGC via a separate binding site independently of NO, increasing cGMP generation and leading to vasodilation.
Sotatercept-csrk is an activin signaling inhibitor that binds to activin A and other TGF-beta superfamily ligands, improving the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation in pulmonary arterial hypertension.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Adempas
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Winrevair
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Adempas
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (6/8)
Winrevair
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (2/8)
Humana
Adempas
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Winrevair
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAdempas Co-pay Assistance Program
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$5/fillfill
Merck Access Co-pay Assistance: WinrevairCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AdempasView full Adempas profile
WinrevairView full Winrevair profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.